Quarterly report · Q1
8129.TEDINET S100OXRX
Period2022-04-01 → 2022-06-30
Filed2022-08-12
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 34
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥323.4bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Revenue | ¥1.27T | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥308.8bn | 2021-04-01 → 2021-06-30 | Cons. | Net sales |
| Operating income | ¥1.4bn | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Operating income | ¥635m | 2021-04-01 → 2021-06-30 | Cons. | Operating income |
| Ordinary income | ¥3.1bn | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥18.2bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.3bn | 2021-04-01 → 2021-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥3.0bn | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥2.4bn | 2021-04-01 → 2021-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.1bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥13.4bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.7bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.1bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Net income | ¥1.7bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss |
| Total assets | ¥710.1bn | at 2022-06-30 | Cons. | Assets |
| Total assets | ¥702.4bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥697.5bn | at 2021-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥466.3bn | at 2022-06-30 | Cons. | Liabilities |
| Total liabilities | ¥461.1bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥243.7bn | at 2022-06-30 | Cons. | Net assets |
| Net assets / equity | ¥241.3bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥237.4bn | at 2021-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥94.4bn | at 2022-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥94.3bn | at 2022-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥29.22 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥189.7 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥24.55 | 2021-04-01 → 2021-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥26.86 | 2022-04-01 → 2022-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥174.48 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥22.55 | 2021-04-01 → 2021-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 34.3% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.3% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.0% | at 2021-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 46
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-06-30 | −¥14.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-06-30 | −¥14.6bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥401m |
| jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥22.2bn |
| jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥22.2bn |
| jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥0 |
| jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥133m |
| jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥2.5bn |
| jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥612m |
| jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥1.9bn |
| jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥288m |
| jpcrp040300-q1r_E02608-000Medical Products Retailreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥311.8bn |
| jpcrp040300-q1r_E02608-000Medical Products Retailreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥299.4bn |
| jpcrp040300-q1r_E02608-000Medical Products Retailreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥12.4bn |
| jpcrp040300-q1r_E02608-000Medical Products Retailreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥1.3bn |
| jpcrp040300-q1r_E02608-000Other Related Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥1.5bn |
| jpcrp040300-q1r_E02608-000Other Related Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥1.2bn |
| jpcrp040300-q1r_E02608-000Other Related Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥356m |
| jpcrp040300-q1r_E02608-000Other Related Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥94m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-06-30 | ¥338.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-06-30 | ¥323.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥14.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-06-30 | ¥1.8bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-06-30 | −¥14.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-06-30 | −¥14.5bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-06-30 | −¥466m |
| jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥22.5bn |
| jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥22.5bn |
| jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥0 |
| jpcrp040300-q1r_E02608-000Dispensing Pharmacyreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥350m |
| jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥1.9bn |
| jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥403m |
| jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥1.5bn |
| jpcrp040300-q1r_E02608-000Medical Products Manufacturing And Salesreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥195m |
| jpcrp040300-q1r_E02608-000Medical Products Retailreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥297.6bn |
| jpcrp040300-q1r_E02608-000Medical Products Retailreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥284.9bn |
| jpcrp040300-q1r_E02608-000Medical Products Retailreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥12.7bn |
| jpcrp040300-q1r_E02608-000Medical Products Retailreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥554m |
| jpcrp040300-q1r_E02608-000Other Related Businessreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥1.3bn |
| jpcrp040300-q1r_E02608-000Other Related Businessreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥966m |
| jpcrp040300-q1r_E02608-000Other Related Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥305m |
| jpcrp040300-q1r_E02608-000Other Related Businessreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥0 |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-06-30 | ¥323.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-06-30 | ¥308.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥14.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-06-30 | ¥1.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 420
| Item | Context | Value | Unit |
|---|---|---|---|
| Previous fiscal year start date | FilingDateInstant | 2021-04-01 | |
| Comparative period end date | FilingDateInstant | 2021-06-30 | |
| Previous fiscal year end date | FilingDateInstant | 2022-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所プライム市場 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)単元株式数は100株であります。 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus | |
| Changes in number of issued shares stated capital etc (text) | FilingDateInstant | Text · Plus | |
| Major shareholders (text) | FilingDateInstant | Text · Plus | |
| Voting rights (text) | FilingDateInstant | Text · Plus | |
| Issued shares voting rights (text) | FilingDateInstant | Text · Plus | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesReciprocalHoldingSharesWithFullVotingRightsTreasurySharesEtcMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | － | |
| Description issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | Original text (Japanese)１単元(100株)未満の株式 | |
| Treasury shares etc (text) | FilingDateInstant | Text · Plus | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)提出会社 | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row1Member | Original text (Japanese)東京都世田谷区代沢５－２－１ | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row2Member | Original text (Japanese)酒井薬品株式会社 | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row2Member | Original text (Japanese)東京都三鷹市野崎１－11－22 | |
| Name of shareholder treasury shares etc | CurrentQuarterInstant_Row3Member | Original text (Japanese)株式会社ヤマトメディカル | |
| Address of shareholder treasury shares etc | CurrentQuarterInstant_Row3Member | Original text (Japanese)熊本県熊本市北区武蔵ケ丘７－２－55 | |
| Information about officers (text) | FilingDateInstant | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYTDDuration | Text · Plus | |
| Note on independent audit financial information | CurrentYTDDuration | Text · Plus | |
| Quarterly consolidated balance sheet (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of income (text) | CurrentYTDDuration | Text · Plus | |
| Year to quarter end consolidated statement of comprehensive income (text) | CurrentYTDDuration | Text · Plus | |
| Notes uncertainties of entitys ability to continue as going concern quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in scope of consolidation or equity method (text) | CurrentYTDDuration | Text · Plus | |
| Notes changes in accounting policies in accordance with changes in accounting standards etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes accounting treatments specific to quarterly financial statements quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |